Moderna Inc.
Vaccine-platform biotech from the Stocktwits list — not part of the AI-discovery thesis (that's TEM/CRSP/RXRX), track separately.
$254.19
+5.27%
Short interest
Short % of float
8.9%
Days to cover
1.8d
Shares short
32.60M
Vs Sep 15
-1%
Shorts are present, but a bounce here is mostly price, not a squeeze.
Why it's this high: price is still near the highs after a large run (up 945% over the past year). Shorts are usually betting it cannot stay there. Volume is heavy, so they can cover in about 1.8 days if it turns.
Share count and days to cover are the latest FINRA settlement. Short % of float is from Finviz. Prints land about twice a month — fuel for a turn, not today's flow.
No upcoming events in tracker — Finnhub may add earnings when scheduled
Yahoo · 19h ago
ChartMill · 1d ago
Next report
2027-02-11 · Q4 2026
EPS est. -1.28 · actual 0.38 (+129.8%)
Last reported · 2026-09-30
Last surprise +129.8% vs estimate
Insider trades (Form 4)
Buys
154,359 sh
$2.2M
Sells
350,165 sh
$81.6M
Net (12 filings)
-195,806 sh
$79.4M net
Hoge Stephen (Option exercise) — 76,452 sh · $19.4M
Hoge Stephen (Open-market sale) — 39,145 sh · $8.6M
Hoge Stephen (Option exercise) — 76,452 sh · $0.9M
Hoge Stephen (Option exercise) — 76,453 sh · $19.4M
Hoge Stephen (Open-market sale) — 450 sh · $0.1M
Hoge Stephen (Open-market sale) — 38,774 sh · $8.3M
Hoge Stephen (Option exercise) — 76,453 sh · $0.9M
Mock James M (Option exercise) — 1,454 sh · $0.4M
Mock James M (Tax withholding) — 704 sh · $0.1M
Mock James M (Option exercise) — 1,454 sh · $0.4M
Hoge Stephen (Option exercise) — 76,452 sh · $19.4M
Hoge Stephen (Open-market sale) — 40,281 sh · $5.9M
RSI, moving averages, MACD, Bollinger bands & candlestick patterns from Yahoo daily data — verify on chart
Above 20-day MA
Price $254.19 vs 20 SMA $224.85
Above 50-day MA
Price $254.19 vs 50 SMA $191.85
Above 200-day MA
Price $254.19 vs 200 SMA $91.47
Near 251-day high
-1.6% from 251-day high ($258.38)
Above 251-day low
1036.8% above 251-day low ($22.36)
Gap up
Opened 1.6% above prior close on 2026-11-06
Price vs 200-day EMA, plus whether profit shows up as cash. Cash flow, cash, capex growth, and interest coverage sit next to the multiple.
128.9% above 200-day EMA
Neither a technical discount nor a fundamentals red flag right now.
Trailing PE
—
Invest rank
29
Swing rank
15
Earnings skew
open
Cash flow/share
−$7.54
Trailing twelve months
Cash/share
$12.95
Latest quarter
Interest cover
—
Operating profit / interest
Price / FCF
114x
After capex
Rev / share
18.9%
Five-year revenue growth per share
Capex growth
24.7%
5-year rate
Gross margin
36.8%
Prior year 70.3%
Revenue growth
13.1%
YoY, TTM or latest quarter
Net margin
-110.5%
TTM profitability
Debt / equity
51.9%
Lower = less leveraged
FCF growth
—
5Y CAGR, capex-aware
Composite fundamentals score: 41/100 · from Finnhub basic financials, verify against the latest 10-Q before acting.